(turmeric), and have received much attention due to their pleiotropic anticancer properties. Recent evidence suggests that curcumin and analogs prevent the activation of a variety of signaling pathways, including the MAPK, PI3K/Akt, and NF-kB pathways, resulting in the induction of apoptosis, prevention of proliferation, and suppression. In addition to these processes, curcumin has been shown to enhance the efficacy of the conventional anti-cancer modalities such as radiation and chemotherapy. By suppressing the expression of matrix metalloproteinases (MMPs), which are enzymes that break down the extracellular matrix and promote cancer cell invasion and metastasis, curcumin also demonstrates anti-metastatic qualities. Inflammation and the advancement of cancer are linked to the NF-κB signaling pathways, which are also suppressed by curcuminoids. Along with these processes, curcumin has demonstrated the ability to improve the effectiveness of traditional cancer treatments, including radiation and chemotherapy. It increases the sensitivity of cancer cells to various therapies, which enhances the therapeutic results. However, curcumin's low bioavailability limits its therapeutic use. Its anticancer potency may be increased, and this restriction may be overcome due to recent developments in drug delivery technologies, such as curcumin-loaded nanoparticles. Since they can target several different molecular pathways and improve the effectiveness of current treatments, curcuminoids are a promising family of chemicals for the prevention and treatment of cancer.
Background Irinotecan is a potent chemotherapeutic agent used as a neoadjuvant in colorectal cancer liver metastasis and significantly enhances five-year survival rates. Recently, irinotecan-associated hepatotoxicity was a significant concern. Given the limited study in this area, we aimed to identify risk factors associated with irinotecan-induced hepatotoxicity. Methods This is a retrospective cohort study at King Saud University Medical City in Riyadh. The study encompassed all adult cancer patients who received irinotecan treatment between Jun 2017 and December 2023. The clinical records of patients were reviewed to assess factors associated with hepatotoxicity. Time-to-event analyses were performed using time-varying exposure. Results The study includes 229 adult cancer patients who received irinotecan-based treatment. Median age was 58 years, and colorectal cancer was the most diagnosed type of cancer (68.6%). Over a median follow-up of 103 days, the incidence of hepatotoxicity was 19.2% (n=44). In the adjusted analysis, higher baseline AST was associated with an increased hazard of hepatotoxicity (HR = 1.01; 95% CI: 1.01–1.02; p = 0.001). Cumulative irinotecan dose showed an inverse association with hepatotoxicity, with lower hazards observed in the medium cumulative dose group (HR = 0.36, 95% CI: 0.14–0.91, p = 0.031) and high cumulative dose group (HR = 0.06, 95% CI: 0.01–0.48, p = 0.008) compared with the low cumulative dose group. Conclusion In summary, an inverse association was observed between cumulative irinotecan dose and hepatotoxicity. A higher baseline AST was also associated with hepatotoxicity, warranting careful assessment of pretreatment liver enzymes and closer monitoring during the early treatment period. Further studies are needed to validate these findings and investigate additional predictors of irinotecan-related hepatotoxicity.
Doxorubicin (DOX) is a commonly prescribed chemotherapeutic agent whose clinical application is limited by its toxicity to rapidly dividing organs, particularly the testes.This study explored the protective potential of ferulic acid-loaded niosomes (FA-NIO) against DOX-induced testicular dysfunction in rats and elucidated the underlying molecular mechanisms. Forty male rats were allocated into four groups: Group 1 was given saline, Group 2 was given DOX, Group 3 was given DOX + free FA, and Group 4 was given DOX + FA-NIO. Serum reproductive hormone levels, testicular oxidative stress indices, and the expression of genes and proteins relevant to NLRP3 inflammasome signaling, apoptosis (Bax and Bcl-2), and steroidogenesis (StAR, CYP11A1, and 3β-HSD) were assessed, along with histopathological changes in the testicular tissue. DOX administration significantly increased MDA (malondialdehyde) while suppressing antioxidant defences, accompanied by hormonal imbalance, severe histopathological damage, upregulation of Bax, NLRP3, and IL-1β, downregulation of Bcl-2, and inhibition of steroidogenic gene expression. On the other hand, these changes were partially mitigated in the DOX + free FA group. Notably, FA-NIO treatment reduced histopathological damage, normalised reproductive hormone levels, markedly increased steroidogenesis-related gene expression, suppressed apoptotic and inflammasome-related gene expression, and greatly restored antioxidant capacity. Compared with DOX + free FA, FA-NIO consistently demonstrated greater protective efficacy. In summary, FA-NIO targets oxidative stress-mediated apoptosis, attenuates NLRP3 inflammasome-related signaling, and restores steroidogenic function, thereby successfully attenuating DOX-induced testicular toxicity. These results suggest that FA-NIO may represent a promising nanotherapeutic strategy for attenuating chemotherapy-induced reproductive toxicity in a rat model.
World Journal of Surgical Oncology · مجلد 23 (1) · 73-73
Globally, oral cancer ranks among the top ten cancers, with a higher prevalence in lower-income countries, where risk factors such as tobacco use, excessive alcohol consumption, and poor oral hygiene are widespread. Metastasis plays a critical role in cancer progression. miR-21 is a crucial regulator of cancer metastasis, profoundly influencing cellular and molecular pathways that contribute to tumour aggressiveness. As a microRNA, miR-21 downregulates tumour suppressor genes, promoting cell proliferation, survival, invasion, and migration. Its role in epithelial-mesenchymal transition (EMT) further facilitates metastatic behaviour. miR-21 also modulates the tumour microenvironment by promoting angiogenesis and altering immune responses, thus enhancing cancer progression.Moreover, miRNA - 21 influences the various signalling pathways like PI3K/ AKT, TGF-β, NF-κB, and STAT3, as well as involved in the cell fate mechanisms known as Autophagy and apoptosis. Clinically, elevated miR-21 levels are associated with poor prognosis, advanced tumour stages, and decreased survival rates, making it a valuable prognostic marker. Additionally, miR-21 expression levels can predict resistance to chemotherapy and targeted therapies, aiding in personalized treatment planning. Therapeutically, targeting miR-21 through anti-miR-21 oligonucleotides, small molecule inhibitors, and miRNA sponges shows promise in pre-clinical studies, potentially inhibiting tumour growth and improving sensitivity to existing treatments. Overall, miR-21's multifaceted role in cancer biology, its prognostic and predictive value, and its potential as a therapeutic target highlight its significance in advancing cancer diagnosis, treatment, and patient outcomes. Further research and clinical trials are essential to exploit miR-21's capabilities in oncology fully.
The revolution in the 21st century has witnessed the development of the industrial and healthcare systems. Human health and well-being are still global challenges despite this modernization and advancement. Cancer is extensively affecting people, demanding special attention and an effective dietary approach. Bioactive compound-based natural therapies are a significant strategy to reduce the cancer burden. Naringenin, a bioactive compound widely distributed in the citrus family and is known for several health-promoting properties, including anticancer activity. The current review highlights the anticancer potential of Naringenin by exploring recent studies through various databases like Google Scholar, PubMed, ScienceDirect, and Web of Science. The analyses revealed that Naringenin can inhibit cell proliferation and oncogenesis through different molecular mechanisms and signaling pathways like apoptosis induction, cell cycle arrest, and modulation of P13K/AKT/mTOR, TGF-β1/Smad3, NF-κB, TLR4, and MAPK pathways. Moreover, it can inhibit inflammatory markers (IL-6, TNF-α, and IL-1β), downregulate oncogenes (Ras, HER2, MYC, and BCR/ABL1), and upregulate tumor suppressor genes (TSGs) such as TP53, PTEN, and BRCA1 and BRCA2 expression. Combining Naringenin with other bioactive compounds, chemotherapy drugs, and nanoformulations is a novel way to enhance its anticancer activity. However, poor bioavailability, stability, and lack of clinical trials and in silico studies hinder its therapeutic potential. Therefore, advanced techniques to enhance its stability and clinical trials regarding anticancer potential are required to validate its promising efficacy. The current review focuses on Naringenin's bioavailability, antioxidant, and anticancer potential through possible mechanisms.
Breast cancer (BC) continues to be the most common cancer affecting women globally, posing significant therapeutic challenges due to limited therapeutic efficacy, non-specific drug targeting, systemic toxicity, and the emergence of chemoresistance. These hurdles emphasize the critical need for novel and effective treatment strategies. Nanomedicine has revolutionized cancer therapy, especially D-alpha-tocopheryl polyethylene glycol succinate (TPGS)-based nanoparticles (TPGS-NPs), which have emerged as a promising strategy due to their enhanced therapeutic potential. TPGS, an amphiphilic derivative of Vitamin E, not only enhances the solubility, stability, and bioavailability of lipophilic drugs but also exhibits intrinsic anti-BC properties. The incorporation of TPGS into NPs significantly enhances their physicochemical properties. Further, the engineering of TPGS-NPs with targeting ligands significantly improves their specificity towards cancer cells. Also, TPGS-NPs show great potential to improve photothermal and photodynamic therapies due to their excellent physicochemical properties. Moreover, TPGS-NPs demonstrate an excellent ability for gene (plasmid DNA, siRNA, and miRNA) delivery by enhancing stability and transfection efficiency. This review explores the multifaceted role of TPGS and the role of different TPGS-NPs in circumventing the limitations of conventional chemotherapy in BC treatment. Overall, developing TPGS-NPs offers a versatile and multifaceted approach to achieve better therapeutic outcomes against BC. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
breast cancertargeted drug deliveryphotothermal therapyphotodynamic therapy
Background Theobromine derivatives have emerged as promising anticancer agents, but their therapeutic potential is limited by poor bioavailability. This study investigates a chitosome-based delivery system for a novel theobromine derivative, N -(4-Chlorophenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1 H -purin-1-yl)acetamide ( T-1-PCPA ), to evaluate its anticancer potential. Methods T-1-PCPA -loaded chitosomess ( T-1-PCPA loaded chitosomes) were formulated using the thin film hydration technique. Molecular docking was employed to computationally assess the stability of the T-1-PCPA loaded chitosomes. Experimentally, various physicochemical properties, including particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency, were analyzed. Transmission electron microscopy (TEM) was used to investigate morphological features. In vitro , the cytotoxicity of the T-1-PCPA -PC-CS was evaluated on HCT-116 and A549 cancer cell lines. Further mechanistic studies included cell cycle analysis, apoptosis detection, and cell migration assays were performed. Results The T-1-PCPA loaded chitosomes exhibited good colloidal stability, with well-defined spherical particles averaging 142.6 ± 4.3 nm in size, a zeta potential of +32.4 ± 1.6 mV, and an entrapment efficiency of 89.2 ± 2.1%, indicating efficient drug loading and formulation stability. In vitro cytotoxicity assays revealed significantly enhanced anticancer activity, with IC 50 values of 8.05 ± 0.06 μg/mL for HCT-116 and 9.55 ± 0.15 μg/mL for A549 cells—substantially lower than those of free T-1-PCPA and blank formulations. Flow cytometric cell cycle analysis demonstrated arrest at G0-G1 and S phases, while apoptosis analysis revealed a significant increase in total apoptosis (39.55%) in treated HCT-116 cells. Cell migration assays showed a 63.4% reduction in migration compared to control, supporting the formulation's anti-migratory potential. Conclusion T-1-PCPA -loaded chitosomes system shows strong potential as a targeted anticancer nanotherapy, demonstrating enhanced cytotoxicity, apoptosis induction, cell cycle arrest, and anti-migratory activity. With high drug loading, stability, and selectivity toward cancer cells, it addresses key limitations of conventional chemotherapy. These findings warrant further preclinical evaluation for colorectal and lung cancer treatment.
chitosomestheobromine derivativesanticancer drug deliverydrug encapsulation
Limb-salvage surgery (LSS) is the cornerstone of modern osteosarcoma management, yet outcomes appear to differ substantially between pediatric and adult patients. Variability in tumor biology, chemotherapy tolerance, treatment intensity, and reconstructive durability may contribute to age-related disparities; however, comparative evidence has not been previously synthesized. This study aimed to systematically evaluate oncologic, functional, and prognostic differences in limb-salvage outcomes between pediatric and adult patients with osteosarcoma. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic review was performed across major databases. Studies were eligible if they reported limb-salvage outcomes separately for pediatric and adult patients. Data extraction encompassed survival, recurrence, functional scores, chemotherapy response, and prognostic factors. Risk of bias was assessed using the Newcastle-Ottawa Scale. Seven studies met the inclusion criteria, representing over 12,000 patients from cooperative trials, national registries, and institutional cohorts. Pediatric patients consistently demonstrated superior oncologic outcomes, with higher five-year overall survival (55%-73% vs. 41%-69%) and lower distant recurrence rates compared with adults. Local recurrence remained low but was slightly more frequent in adults. Functional outcomes favored pediatric groups, who achieved higher MSTS scores and lower revision rates. Histologic response to chemotherapy ≥90% was substantially more common in children, reflecting stronger systemic treatment tolerance. Predictors of poor outcome, such as axial site, metastatic disease, comorbidities, and poor necrosis, were disproportionately represented in adult cohorts. Risk of bias was low to moderate for most studies, with consistent age-related patterns across all evidence sources. Age significantly influences outcomes following LSS for osteosarcoma. Pediatric patients show superior survival, lower recurrence, improved function, and more favorable prognostic indicators compared with adults, even within similar surgical pathways. Biological differences, treatment intensity, and systemic therapy responsiveness likely contribute to these disparities. Future research should focus on optimizing chemotherapy strategies and reconstructive approaches for adults and on identifying biologic drivers that underlie these age-dependent patterns.
osteosarcomalimb salvagechildren versus adultsage disparities
This study aimed to assess the possible consequences of spirulina (SP) and/or L-carnitine (L-car) on the prevention of primordial follicular reserve depletion and the preservation of ovarian follicular structure and function in a rat model of premature ovarian insufficiency (POI). Forty healthy adult female Sprague-Dawley albino rats were randomly assigned into five equal-sized groups (n = 8): normal control, DOX group (2.5 mg/kg i.p.), SP group (500 mg/kg intragastric), L-car group (250 mg/kg i.p.), and SP + L-car group in the same previous doses. In comparison to the DOX group, administration of either SP or L-car significantly increased serum E2 and AMH levels along with a significant decrease in the FSH and LH levels (p < 0.05). The oxidative stress was significantly reduced. Ovarian expressions of NF-κB, iNOS, FOXO1, P53, and caspase-3 decreased significantly, while SIRT1, STAR, CYP17A1, HSD17B3, Nrf2, and mtDNA increased significantly. Histology revealed histoarchitecture improvement as the mean % of atretic follicles and degenerated corpora lutea was significantly reduced (p < 0.05). The combined treatments synergistically improved the parameters studied more than either treatment alone. The molecular docking results revealed the ability of both n-hexadecanoic acid and L-carnitine to activate SIRT1 and subsequent antioxidant, anti-inflammatory, and anti-apoptotic pathways. This ovoprotective effect is suggested to be mediated through activation of different SIRT1-mediated protective signaling pathways that remodel ovarian redox status, inflammation, and apoptosis, which may strengthen the potential role of SP and L-car as a chemotherapy adjuvant, reducing the negative health effects of early menopause after cancer therapy.
Journal of Advanced Trends in Medical Research · مجلد 2 (4) · 671-681
Hair loss, or alopecia, encompasses a diverse range of conditions including both cicatricial (scarring) and non-cicatricial (non-scarring) forms, with significant implications for patients’ physical appearance, psychological well-being and overall quality of life. The limitations of traditional therapies such as topical agents, oral medications and hair transplantation have led to increasing interest in regenerative approaches. Amongst these, platelet-rich plasma (PRP) and exosome-based therapies have emerged as promising biologic interventions. PRP, derived from autologous blood, contains a high concentration of platelets rich in growth factors that support hair follicle regeneration, angiogenesis and cellular proliferation. Evidence suggests its potential benefits in various types of hair loss particularly androgenetic alopecia, alopecia areata and telogen effluvium, although standardised protocols, optimal dosing and long-term outcomes remain uncertain. Exosomes are small extracellular vesicles secreted by stem cells that offer a novel cell-free alternative capable of delivering complex molecular signals to modulate inflammation, stimulate follicular stem cells, and promote dermal remodeling. Early findings indicate possible applications across a range of alopecias including chemotherapy-induced hair loss, autoimmune related alopecia and structural hair shaft disorders such as trichorrhexis nodosa and monilethrix. This narrative review provides an updated overview of PRP and exosome-based therapies, outlining their mechanisms of action, clinical applications and current limitations. While both modalities show therapeutic promise, their biologic variability, lack of regulatory standardisation and need for comparative trials highlight critical gaps in evidence. Further research is warranted to establish reproducible treatment protocols and determine long-term efficacy and safety for clinical use.
Journal of Orthopaedic Surgery and Research · مجلد 20 (1) · 715-715
BACKGROUND: The treatment of musculoskeletal (MSK) tumors involving the extremities has evolved over the past decade with the introduction of prosthesis and new chemotherapy regimen. The Toronto Extremity Salvage Score system (TESS) is a patient-filled questionnaire that measures the functional status of patients with MSK tumors who underwent limb-salvaging procedure. The purpose of this study is to translate TESS into Arabic (TESS-AR) and to examine its reliability and validity. METHODS: Our study is a multi-center in Riyadh, Saudi Arabia. Arabic-speaking adults diagnosed with MSK tumors involving the extremities were included. TESS-AR was created following clear, user-friendly guidelines for translation. Moreover, reliability and validity were measured using the test-retest method and construct validity, respectively. RESULTS: 108 participants completed the TESS-AR, 56% had lower limb tumors. The participants reported that the TESS-AR was clear and all questions and answers were understood. The test-retest reliability showed excellent reliability, with an interclass correlation coefficient of 0.965 for both the lower and upper extremity TESS-AR. Cronbach's alpha of lower extremity TESS-AR was 0.972, whereas that of upper extremity TESS-AR was 0.969, indicating strong internal consistency. The construct validity between TESS-AR and SF-36 showed a strong and moderated correlation between most of the components, with a Pearson correlation coefficient >0.40. Similar results were found between TESS-AR and EORTC QLQ C30. CONCLUSION: The TESS-AR is a comprehensible, valid, and reliable score for assessing functional outcomes in patients with extremity tumors. We believe that TESS-AR can be used by clinicians, researchers, and patients alike.
Toronto Extremity Salvage ScoreArabic translationcross-cultural adaptationmusculoskeletal tumors
Synchronous colorectal and small bowel adenocarcinomas are exceptionally rare. This case report presents a 65-year-old male patient with acute bowel obstruction who underwent an emergency laparotomy. Intraoperative findings revealed synchronous sigmoid colon and small bowel tumors with peritoneal metastases. The patient underwent sigmoidectomy, small bowel resection, and metastasectomy. Histopathology confirmed two distinct primary adenocarcinomas. Postoperative management included KRAS mutation-guided chemotherapy. At the two-year follow-up, the patient remained disease-free. This case highlights the importance of thorough intraoperative exploration in emergency presentations and demonstrates the potential for favorable outcomes with aggressive multimodal treatment in synchronous gastrointestinal malignancies.
small bowel adenocarcinomasigmoid colon canceracute intestinal obstructionperitoneal carcinomatosis
Abstract Background Colorectal cancer (CRC) is a type of cancer that affects the colon or rectum and occurs in individuals over the age of 50, although it can affect people of all ages. Quercetin is a flavonoid, which is a type of plant pigment with antioxidant and anti-inflammatory properties. Some studies have explored the potential of quercetin as an adjuvant therapy to enhance the effectiveness of chemotherapy or radiation therapy. Methodology In the proposed work, the nano-biomaterials of solid lipids such as stearic acid (SA) and tripalmitin (TpN) as well as the surfactants tween 80 and span 80 were used to prepare novel quercetin (QuR)-loaded-solid lipid nanoparticles (QuR-SLNs) for medical applications in colorectal cancer (CRC). The resulting bio-nano SLNs’ mean entrapment efficiency (EE) and particle size (PS) were optimized by Box–Behnken design (BBD) approach based on the response-like surface methodology (RSM). The variables include lipid ratio ( X 1 ), surfactant ratio ( X 2 ), QuR-to-lipid ratio ( X 3 ), the sonication time ( X 4 ), and the homogenization time ( X 5 ). Requirements on the maximum EE (%) and minimum PS (nm) were optimized for the preparation of QuR-SLN. Differential scanning calorimetry (DSC), X-ray diffraction (XRD) analysis, and scanning electron microscopy (SEM) were then used to analyze the optimized SLN and to find the crystalline state of QuR with lipid relationship. In addition, on the Caco-2 cells, at IC 50 (49 µM/mL), in vitro cytotoxicity was attained. Results The optimized QuR-SLN had practically spherical shapes, with % EE and a PS of 97.8 ± 1.16% and 132.16 ± 4.1 nm, respectively. In aqueous media, the degree of lipid crystallinity and the lipid modification was investigated, and the QuR incorporation and release patterns showed high correlations with both. The results showed that over 41.12 ± 1.6% of the bio-nano QuR-SLNs was released gradually over the course of 48 h, demonstrating effective QuR delayed release. Results on apoptotic observations indicate that apoptosis accounts for the majority of cell death, while necrosis, a type of cell death, constitutes a very minor portion. In conclusion, the prepared bio-nano QuR-SLNs might improve cytotoxicity and can act as an ideal carrier for the delivery of QuR and this preparation is used in the treatment of CRC.
Oral squamous cell carcinoma (OSCC) is a highly malignant and invasive tumor with significant mortality and morbidity. Current treatment modalities such as surgery, radiotherapy, and chemotherapy encounter significant limitations, such as poor targeting, systemic toxicity, and drug resistance. There is an urgent need for novel therapeutic strategies that offer targeted delivery, enhanced efficacy, and reduced side effects. The advent of lipid-based nanoparticles (LNPs) offers a promising tool for OSCC therapy, potentially overcoming the limitations of current therapeutic approaches. LNPs are composed of biodegradable and biocompatible lipids, which minimize the risk of toxicity and adverse effects. LNPs can encapsulate hydrophobic drugs, improving their solubility and stability in the biological environment, thereby enhancing their bioavailability. LNPs demonstrate significantly higher ability to encapsulate lipophilic drugs than other nanoparticle types. LNPs offer excellent storage stability, minimal drug leakage, and controlled drug release, making them highly effective nanoplatforms for the delivery of chemotherapeutic agents. Additionally, LNPs can be modified by complexing them with specific target ligands on their surface. This surface modification allows the active targeting of LNPs to the tumors in addition to the passive targeting mechanism. Furthermore, the PEGylation of LNPs improves their hydrophilicity and enhances their biological half-life by reducing clearance by the reticuloendothelial system. This review aims to discuss current treatment approaches and their limitations, as well as recent advancements in LNPs for better management of OSCC.
oral squamous cell carcinomalipid nanoparticlestargeted drug deliverychemotherapy